April 21, 2024

The Endocrine Therapy Drugs (Etds) Market Will Grow At Highest Pace Owing To Increasing Prevalence Of Hormonal Cancers

ETDs work by blocking the body’s natural hormones or by stopping the cancer cells from responding to hormonal signals. Some of the commonly prescribed ETDs include tamoxifen, aromatase inhibitors like anastrozole, letrozole and exemestane. ETDs are mostly prescribed as adjuvant therapy after surgery to lower the risk of cancer recurrence or progression. They are also used as neoadjuvant therapy before surgery or radiation therapy to shrink tumors.

The Global Endocrine Therapy Drugs (ETDs) Market is estimated to be valued at US$ 35060.96 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2030.

Key Takeaways
Key players operating in the Endocrine Therapy Drugs (ETDs) market are Johnson & Johnson (US), Procter & Gamble (US), Kimberly-Clark (US), Essity Aktiebolag (publ) (Sweden), Kao Corporation (Japan), Daio Paper Corporation (Japan), Unicharm Corporation (Japan), Premier FMCG (South Africa), Ontex (Belgium), Hengan International Group Company Ltd. (China), Drylock Technologies (Belgium), Natracare LLC (US), First Quality Enterprises, Inc. (US), Bingbing Paper Co., Ltd. (China). Johnson & Johnson and Procter & Gamble dominate the ETDs market with their large product portfolios.

The growth in the prevalence of hormonal cancers like breast and prostate cancer is driving the demand for ETDs. According to WHO, breast cancer is the most common cancer in women with an estimated 2.3 million new cases in 2020. Prostate cancer is also on the rise globally.

Technological advancements are allowing development of newer Global Endocrine Therapy Drugs (Etds) Market Size with improved efficacy and tolerability. Companies are focused on research studies to discover novel mechanisms of action and agents that can be used in combination with existing drugs to enhance treatment outcomes.

Market Trends
Rise in generic drugs: Patent expirations of major cancer drugs is providing opportunities for generic and biosimilar versions to enter the market at lower prices. This is positively impacting the overall ETDs market growth.

Increasing demand for combination therapies: Clinical research is ongoing to evaluate combination regimens using ETDs along with chemotherapy, CDK4/6 inhibitors or other targeted therapies to improve treatment response over monotherapies.

Market Opportunities
Untapped emerging markets: Developing regions like Asia Pacific, Middle East and Latin America offer significant business potential for ETDs companies due to growing patient pools and increasing access to healthcare.

Novel targeted therapies: Companies are investing in R&D of next-gen endocrine agents targeting new predictive biomarkers and pathways to combat resistances associated with current drugs. This will allow advancement towards precision cancer care.

Impact of COVID-19 on Endocrine Therapy Drugs (ETDs) Market
The COVID-19 pandemic has significantly impacted the growth of the ETDs market. During the initial outbreak, the market registered a decline in growth as non-essential medical procedures were postponed. The disruption in manufacturing and supply chains also affected the production and distribution of ETDs. However, with the resumption of healthcare services and focus on chronic disease management post lockdowns, the demand and consumption of ETDs increased once again.

The pandemic highlighted the importance of chronic disease management and the need for effective hormonal therapies. It encouraged patients to continue their therapies for conditions like breast cancer without interruption. Telehealth services also supported continuous monitoring and prescription refills during lockdowns. Manufacturers ramped up production with safety protocols to meet the growing demand for hormonal drugs. Several drugs showed potential against COVID-19 symptoms which increased research activities.

The long-term impact of the pandemic is expected to drive the Global Endocrine Therapy Drugs (Etds) Market Sizegrowth. With the growing risk of chronic diseases like cancer due to COVID-19 infections, hormonal therapies will be crucial for treatment and management. Telehealth is likely to provide continued care facilitating market expansion. Government initiatives for cancer screening programs postponed during the pandemic will identify new patients. Collaborations for clinical trials evaluating drug efficacy against COVID-19 can generate new revenue streams. While short-term sales were affected, the growing disease burden and innovations will support the market in reaching its forecasted value over the next few years.

Geographical regions where Endocrine Therapy Drugs (ETDs) market is concentrated in terms of value:

North America dominates the ETDs market and holds the highest value share. This can be attributed to factors like the increasing incidence of hormone-related cancers, advanced healthcare infrastructure and widespread health insurance. According to the American Cancer Society, approximately 286,200 new cases of breast cancer were reported in the US in 2022 making it the most prevalent cancer. Availability of favorable reimbursements for hormonal therapies in the US and Canada boost market revenues.

Europe is the second largest regional market for ETDs due to major countries like Germany, U.K. and France reporting a high burden of cancer patients opting for hormonal regimens. The growing geriatric population susceptible to hormonal dysfunction augments demand. Asia Pacific is witnessing fastest ETDs market growth aided by rising cancer awareness, improving access to diagnosis and treatment in nations like China, India and Japan.

Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it